Compugen to Present at SITC 2025
Compugen (Nasdaq: CGEN) will present clinical data from an ongoing first‑in‑human trial of the anti‑IL18BP antibody COM503 (GS‑0321) at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on November 7–9, 2025 in National Harbor, Maryland.
The poster (Abstract 589) — titled "A First in human clinical trial to assess the anti‑IL18BP antibody, COM503 (GS‑0321) in Participants with Advanced Solid Malignancies" — will be presented by Dr. Manish Sharma on Friday, November 7, 2025. The company described COM503 as part of an ongoing trial in participants with advanced solid malignancies.
Compugen (Nasdaq: CGEN) presenterà dati clinici da uno studio in essere sull'anticorpo anti‑IL18BP COM503 (GS‑0321) al 40° Congresso Annuale della Society for Immunotherapy of Cancer (SITC) che si svolgerà dal 7 al 9 novembre 2025 a National Harbor, Maryland.
Il poster (Abstract 589) — intitolato "Uno studio clinico per l'uomo al primo utilizzo per valutare l'anticorpo anti‑IL18BP, COM503 (GS‑0321) in partecipanti con neoplasie solide avanzate" — sarà presentato dal Dr. Manish Sharma il venerdì 7 novembre 2025. L'azienda ha descritto COM503 come parte di uno studio in corso in partecipanti con neoplasie solide avanzate.
Compugen (Nasdaq: CGEN) presentará datos clínicos de un ensayo en humanos en curso sobre el anticuerpo anti‑IL18BP COM503 (GS‑0321) en la 40.ª Reunión Anual de la Society for Immunotherapy of Cancer (SITC), que se celebrará del 7 al 9 de noviembre de 2025 en National Harbor, Maryland.
El cartel (Resumen 589) — titulado "Un ensayo clínico en primera persona para evaluar el anticuerpo anti‑IL18BP, COM503 (GS‑0321) en participantes con neoplasias sólidas avanzadas" — será presentado por el Dr. Manish Sharma el viernes 7 de noviembre de 2025. La empresa describió COM503 como parte de un ensayo en curso en participantes con neoplasias sólidas avanzadas.
컴퓨젠(나스닥: CGEN)은 40번째 연례 학술대회 SITC에서 진행 중인 HUMAN 대상 최초 임상시험의 항 IL18BP 항체 COM503 (GS-0321)에 대한 임상 데이터를 발표할 예정이며, 2025년 11월 7–9일에 메릴랜드주 내셔널 하버에서 개최됩니다.
포스터(초록 589) — 제목은 "고도 진행된 고형 악성 종양을 가진 참가자에서 항 IL18BP 항체 COM503 (GS-0321)의 1상 임상시험 평가" — 은 맨니시 샤르마 박사가 2025년 11월 7일 금요일에 발표할 예정입니다. 회사는 COM503를 고형 악성 종양 참가자를 대상으로 한 진행 중인 임상시험의 일부로 설명했습니다.
Compugen (Nasdaq: CGEN) présentera des données cliniques d'un essai chez l'homme en cours concernant l'anticorps anti‑IL18BP COM503 (GS‑0321) lors de la 40e réunion annuelle de la Society for Immunotherapy of Cancer (SITC), qui se tiendra du 7 au 9 novembre 2025 à National Harbor, Maryland.
Le poster (Abstract 589) — intitulé « Premier essai clinique chez l'homme pour évaluer l'anticorps anti‑IL18BP, COM503 (GS‑0321) chez des participants atteints de carcinomes avancés » — sera présenté par le Dr Manish Sharma le vendredi 7 novembre 2025. L'entreprise décrit COM503 comme faisant partie d'un essai en cours chez des participants atteints de néoplasies solides avancées.
Compugen (Nasdaq: CGEN) wird klinische Daten aus einer laufenden ersten humanen Studie des Anti‑IL18BP‑Antikörpers COM503 (GS‑0321) auf der 40. Jahrestagung der Society for Immunotherapy of Cancer (SITC) vom 7. bis 9. November 2025 in National Harbor, Maryland, vorstellen.
Der Poster (Abstract 589) — mit dem Titel „Eine First in Human-Studie zur Bewertung des Anti‑IL18BP‑Antikörpers COM503 (GS‑0321) bei Teilnehmern mit fortgeschrittenen soliden Malignomen“ — wird von Dr. Manish Sharma am Freitag, dem 7. November 2025 vorgestellt. Das Unternehmen beschreibt COM503 als Teil einer laufenden Studie bei Teilnehmern mit fortgeschrittenen soliden Malignomen.
Compugen (نِظام ناسداك: CGEN) ستعرض بيانات سريرية من تجربة بشرية أولى جارية للمُضاد IL18BP COM503 (GS‑0321) في الاجتماع السنوي الأربعين لجمعية المناعة العلاجية للسرطان (SITC) في 7–9 نوفمبر 2025 في National Harbor، ماريلاند.
سيُقدم الملصق (الملخص 589) — بعنوان "تجربة سريرية لأول مرة لتقييم مضاد IL18BP COM503 (GS‑0321) لدى مشاركين مصابين بسرطان صلب متقدم" — من قبل د. مانيش شارما في الجمعة 7 نوفمبر 2025. وصفت الشركة COM503 كجزء من تجربة جارية لدى المشاركين المصابين بأورام صلبة متقدمة.
Compugen (纳斯达克：CGEN) 将在癌症免疫治疗学会（SITC）第四十届年度会议上，公布正在进行的首次人体试验的抗 IL18BP 抗体 COM503 (GS‑0321) 的临床数据，会议于 2025 年 11 月 7–9 日 在马里兰州 National Harbor 举行。
海报（摘要 589）——题为“首次在人类中评估抗 IL18BP 抗体 COM503 (GS‑0321) 在晚期实体瘤患者中的临床试验”——将由 Manish Sharma 博士 于 2025 年 11 月 7 日（星期五） 발표。公司将 COM503 描述为正在进行的、针对晚期实体瘤患者的临床试验的一部分。
- None.
- None.
HOLON,
Poster presentation details:
Abstract Title: A First in human clinical trial to assess the anti-IL18BP antibody, COM503 (GS-0321) in Participants with Advanced Solid Malignancies
Abstract number: 589
Presenter: Dr. Manish Sharma, MD, Co-Director of Clinical Research, START Midwest,
Date: Friday, November 7, 2025
About Compugen
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive AI/ML powered computational discovery platform (Unigen™) to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. GS-0321 (previously COM503), a potential first-in-class, high affinity anti-IL-18 binding protein antibody, which is in Phase 1 development, is licensed to Gilead. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of research programs aiming to address new mechanisms to activate the immune system against cancer. Compugen is headquartered in
Company contact:
Yvonne Naughton, Ph.D.
Vice President, Head of Investor Relations and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original content:https://www.prnewswire.com/news-releases/compugen-to-present-at-sitc-2025-302575665.html
SOURCE Compugen Ltd.
FAQ
When will Compugen (CGEN) present COM503 data at SITC 2025?
What is the title and abstract number for Compugen's SITC 2025 presentation (CGEN)?
Who is presenting Compugen's COM503 poster at SITC 2025 (CGEN)?
What clinical trial stage is Compugen's COM503 (GS‑0321) program (CGEN)?
Will Compugen disclose efficacy or safety results for COM503 at SITC 2025 (CGEN)?
